Table 2.
Demographic & Clinical Characteristics
| Pre-ERAS (n = 58) | ERAS (n = 213) | All Patients (n = 271) | p-value | ||
|---|---|---|---|---|---|
| Age, y | Median (Min, Max) | 58.0 (32.0, 85.0) | 59.0 (18.0, 79.0) | 59.0 (18.0, 85.0) | 0.808 |
| Length of Stay, d | Median (Min, Max) | 4.0 (2.0, 29.0) | 3.0 (1.0, 57.0) | 3.0 (1.0, 57.0) | < 0.001 |
| Surgical Time, min | Median (Min, Max) | 221.5 (98.0, 484.0) | 210.0 (33.0, 497.0) | 211.0 (33.0, 497.0) | 0.271 |
| Estimated Blood Loss, mL | Median (Min, Max) | 300.0 (40.0, 3500.0) | 250.0 (10.0, 2700.0) | 250.0 (10.0, 3500.0) | 0.095 |
| Race | White or Caucasian | 48 (82.8%) | 152 (71.4%) | 200 (73.8%) | 0.151 |
| Black or African American | 2 (3.4%) | 29 (13.6%) | 31 (11.4%) | ||
| Asian | 1 (1.7%) | 7 (3.3%) | 8 (3.0%) | ||
| Other | 5 (8.6%) | 21 (9.9%) | 26 (9.6%) | ||
| Unknown | 2 (3.4%) | 4 (1.9%) | 6 (2.2%) | ||
| Ethnicity | Hispanic or Latino | 12 (20.7%) | 28 (13.1%) | 40 (14.8%) | 0.333 |
| Not Hispanic or Latino | 43 (74.1%) | 174 (81.7%) | 217 (80.1%) | ||
| Unknown | 3 (5.2%) | 11 (5.2%) | 14 (5.2%) | ||
| Body Mass Index (kg/m2) | < 18.5 | 1 (1.7%) | 5 (2.3%) | 6 (2.2%) | 0.957 |
| 18.5 – 24.9 | 15 (25.9%) | 67 (31.5%) | 82 (30.3%) | ||
| 25.0 – 29.9 | 21 (36.2%) | 66 (31.0%) | 87 (32.1%) | ||
| 30.0 – 34.9 | 11 (19.0%) | 42 (19.7%) | 53 (19.6%) | ||
| 35.0 – 39.9 | 6 (10.3%) | 19 (8.9%) | 25 (9.2%) | ||
| ≥ 40 | 4 (6.9%) | 14 (6.6%) | 18 (6.6%) | ||
| ASA Score | I | - | 1 (0.5%) | 1 (0.4%) | 0.435 |
| II | 13 (22.4%) | 28 (13.8%) | 41 (15.7%) | ||
| III | 44 (75.9%) | 169 (83.3%) | 213 (81.6%) | ||
| IV | 1 (1.7%) | 5 (2.5%) | 6 (2.3%) | ||
| Charlson Comorbidity Index | 0 | 6 (10.3%) | 20 (9.4%) | 26 (9.6%) | 0.928 |
| 1–2 | 22 (37.9%) | 79 (37.1%) | 101 (37.3%) | ||
| ≥ 3 | 30 (51.7%) | 114 (53.5%) | 144 (53.1%) | ||
| Tumor Type | Malignant | 52 (89.7%) | 179 (84.0%) | 231 (85.2%) | 0.634 |
| Benign | 6 (10.3%) | 31 (14.6%) | 37 (13.7%) | ||
| Unavailable | - | 3 (1.4%) | 3 (1.1%) | ||
| Tumor Site a | Cervix | 1 (1.9%) | 7 (3.9%) | 8 (3.5%) | 0.550 |
| Ovary | 35 (67.3%) | 110 (61.5%) | 145 (63.7%) | ||
| Uterine | 7 (13.5%) | 38 (21.2%) | 45 (19.5%) | ||
| Other | 1 (1.9%) | 1 (0.5%) | 2 (0.9%) | ||
| Recurrent Disease | 8 (15.4%) | 28 (15.6%) | 36 (15.6%) | ||
| 30-day Complications, Grade I-IV b | 25 (43.1%) | 82 (38.5%) | 107 (39.5%) | 0.547 | |
| Reoperation | 3 (5.2%) | 4 (1.9%) | 7 (2.6%) | 0.170 | |
| Readmission | 8 (13.8%) | 27 (12.7%) | 35 (12.9%) | 0.826 | |
| Surgical Complexity c | Low | 20 (54.1%) | 78 (68.4%) | 98 (64.9%) | 0.153 |
| Intermediate | 15 (40.5%) | 34 (29.8%) | 49 (32.5%) | ||
| High | 2 (5.4%) | 2 (1.8%) | 4 (2.6%) |
a
: No disease site specified for benign disease.
b
: Complications were graded using Clavien-Dindo perioperative complication classification.
c
: Degree of surgical complexity considered as a variable for cases of ovarian, fallopian tube, or primary peritoneal cancer. All column values are numerical count and percentage unless indicated otherwise. The denominator in the calculation of column percentages for tumor site is the number of patients with malignant disease [52 for pre-ERAS; 179 for ERAS; 231 for all patients]. Abbreviations: ASA, American Society of Anesthesiologists; ERAS, Enhanced Recovery After Surgery.